Dr. Pegram on Margetuximab Plus Chemo in HER2+ Breast Cancer
February 1st 2017Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses the ongoing phase II SOPHIA trial, which is comparing the combination of margetuximab plus chemotherapy with trastuzumab (Herceptin) in patients with HER2-positive breast cancer.
Read More
Dr. Pegram on Challenges in Neoadjuvant Treatment for HER2-Positive Breast Cancer
February 28th 2015Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, goes over some of the challenges surrounding neoadjuvant treatment for HER2-positive breast cancer patients.
Read More
Dr. Pegram on a Phase II Trial of MGAH22 in Breast Cancer
June 1st 2014Mark D. Pegram, MD, from the Stanford University Medical Center, discusses a phase II study of margetuximab in patients with relapsed or refractory advanced breast cancer whose tumors express HER2 at the 2+ level by immunohistochemistry and lack evidence of HER2 gene amplification by FISH.
Read More